← FDA DRUG APPROVALS

FDA ANDA · ANDA065491

MYCOPHENOLATE MOFETIL

Sponsor: TEVA PHARMS

APPLICATION
ANDA065491
TYPE
ANDA
ORIGINAL APPROVAL
2009-05-06
LATEST ACTION
2026-07-29
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

MYCOPHENOLATE MOFETILPrescription
MYCOPHENOLATE MOFETIL 250MG · CAPSULE · ORAL

Approval history

2026-07-29REMS · Supplement 34AP
2024-08-13REMS · Supplement 30AP
2021-08-11REMS · Supplement 23AP
2021-04-21REMS · Supplement 22AP
2021-01-15REMS · Supplement 21AP
2020-08-04Labeling · Supplement 19 · standardAP
2019-09-10Labeling · Supplement 18 · standardAP
2019-09-10Labeling · Supplement 17 · standardAP
2015-11-13REMS · Supplement 9AP
2015-10-30Labeling · Supplement 10 · standardAP
2013-09-27Labeling · Supplement 8 · standardAP
2012-09-25REMS · Supplement 6AP
2012-07-25Labeling · Supplement 7 · standardAP
2010-02-04Labeling · Supplement 5AP
2010-02-02Labeling · Supplement 4AP
2009-05-06OriginalOther Important Information from FDAAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →